Home›Screener›RCUS›Profile
D
38/100

Arcus Biosciences

RCUSImmuno-Oncology
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Arcus Biosciences (RCUS) is the lead sponsor of 10 active clinical trials listed on ClinicalTrials.gov[4], including 3 Phase 3[1], 2 Phase 2[2], 5 Phase 1[3].

Trial NCT05568095[5] evaluates Domvanalimab in Advanced Upper Gastrointestinal Tract Adenocarcinoma with a target enrollment of 1040 participants. Trial NCT07011719[6] evaluates Casdatifan in Metastatic Clear Cell Renal Cell Carcinoma with a target enrollment of 720 participants. Trial NCT06608927[7] evaluates Quemliclustat in Metastatic Pancreatic Ductal Adenocarcinoma with a target enrollment of 610 participants.

No Form 4 insider filings for RCUS were recorded at the SEC in the past 30 days[8].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. ClinicalTrials.gov (2026-04-11) ↗
  5. ClinicalTrials.gov · NCT05568095 (2026-04-02) ↗
  6. ClinicalTrials.gov · NCT07011719 (2026-04-01) ↗
  7. ClinicalTrials.gov · NCT06608927 (2026-04-01) ↗
  8. SEC EDGAR · 0001724521 (2026-04-11) ↗
🔬
Clinical Trials
10
NCT04104672Advanced Pancreatic Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT04736173Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05329766Gastrointestinal Tract Malignancies
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05536141Clear Cell Renal Cell Carcinoma, Solid Tumors
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05568095Advanced Upper Gastrointestinal Tract Adenocarcinoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05891171Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06120075Advanced Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07364214Healthy Participants
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Immuno-Oncology)
AGENAgenus Inc
C
CLDXCelldex Therapeutics
C
JANXJanux Therapeutics
D
ARQTArcus Biosciences
F
Data Provenance
cik1 verified
clinical trial10 verified
insider buy1 verified
trial count4 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR